

Short Communication

Revolutionizing Addiction Treatment: A Comparative Analysis of ReNAD Biologics' NAD⁺ Therapy and Traditional Buprenorphine Protocols

Luke Dandrea^{1*} and Paul Laband²¹ReNAD Biologics Corp, USA²Hospice Medical Director, USA***Corresponding author**Luke Dandrea, ReNAD Biologics Corp, USA, Email: Luke@renadrecovery.com

Submitted: 21 March 2024

Accepted: 17 April 2024

Published: 20 April 2024

ISSN: 2333-665X

Copyright

© 2024 Dandrea L, et al

OPEN ACCESS

Abstract

In an era where the opioid crisis is intensified by escalating fentanyl overdoses and daunting rehabilitation relapse rates, this pioneering study introduces ReNAD Biologics' ReNAD FTP-875 as a beacon of hope. Through a meticulous comparison with established buprenorphine treatments using the Clinical Opiate Withdrawal Scale (COWS), we unveil a groundbreaking reduction in withdrawal symptoms, heralding a new era in addiction medicine.

INTRODUCTION

Confronted with a 537% spike in fentanyl overdoses and a staggering 85% relapse rate within a year post-rehabilitation, the public health landscape demands a revolutionary approach.

Traditional pharmacological interventions falter, unable to fully address the multifaceted nature of opioid addiction. ReNAD Biologics steps into this void with ReNAD FTP-875, a novel NAD⁺ therapy poised to redefine addiction treatment at its cellular core.

METHODS

Clinical Opiate Withdrawal Scale (COWS): A precise tool assessing opiate withdrawal severity, serving as the bedrock for our comparative analysis [1].

Participants

Our study bifurcates patients into two groups, juxtaposing those undergoing ReNAD FTP-875 therapy against individuals receiving traditional buprenorphine treatment [2].

Treatment Protocols

ReNAD FTP-875 distinguishes itself with a bespoke 8-12 day NAD⁺ IV therapy, enriched with a suite of biologics tailored to each patient's unique genetic and physiological blueprint, offering a stark contrast to conventional buprenorphine methodologies.

RESULTS

The efficacy of ReNAD FTP-875 is unequivocally demonstrated through a precipitous decline in COWS scores to ≤ 4 within the initial 30 minutes, a stark divergence from the trajectory observed in buprenorphine treatments [2], which saw an increase in COWS scores from 14 to 21 over 21 hours. This not only underscores the potency of ReNAD FTP-875 but also highlights the inadequacy of existing treatment protocol.

DISCUSSION

Our findings do not merely signal a methodological advancement but ignite a paradigm shift towards a highly personalized, genomic, and biomarker-informed approach in addiction medicine. Aligning with the National Institute on Drug Abuse's (NIDA) and the Surgeon General's advocacy for personalized medicine, our study champions the integration of precision medicine in addiction treatment, setting a precedent for reducing relapse risks and bridging critical gaps in current treatment frameworks.

In addition to the groundbreaking use of precision medicine, ReNAD Biologics' approach is further distinguished by its unique and patent-pending AI-driven analytics platform. This cutting-edge technology analyzes a vast array of patient data, including genomic information, biomarkers, and response to therapy, enabling the optimization of NAD⁺ therapy protocols. By employing AI, ReNAD Biologics not only enhances the personalization of treatment but also pioneers a new frontier

in the predictive analysis of addiction treatment outcomes. The uniqueness of this platform, coupled with its pending patent, positions ReNAD Biologics at the forefront of technological innovation in addiction medicine. This integration of AI underscores [3,4].

Our commitment to leveraging the latest technological advancements to combat the opioid crisis, offering a novel and proprietary approach that sets new standards in the field.

CONCLUSION

ReNAD Biologics' ReNAD FTP-875 emerges not just as a superior alternative to conventional buprenorphine protocols but as a harbinger of transformative change in addiction medicine. By markedly alleviating withdrawal symptoms and fostering

sustained recovery, this personalized treatment paradigm beckons a new dawn in the fight against opioid addiction. The imperative for expansive future research to amplify these findings and explore the broader spectrum of NAD+ therapy's applications in addiction treatment is evident, marking a significant stride towards mitigating the opioid crisis's impact on society [5].

REFERENCES

1. Clinical Opiate Withdrawal Scale (COWS). 2003; 35.
2. Study on Buprenorphine Treatment.
3. ReNAD Biologics Program Data. 2023.
4. Medicine in Addiction Treatment.
5. CDC Reports on Fentanyl Overdoses and Rehab Relapse Rates.